Phenibut for Health & Longevity

Evidence Review created on 11/01/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: β-Phenyl-γ-aminobutyric acid, β-Phenyl-GABA, Phenyl-GABA, 4-Amino-3-phenylbutanoic acid, β-(Aminomethyl)benzenepropanoic acid, beta-(Aminomethyl)hydrocinnamic acid, Aminophenylbutyric acid, Phenibut HCl, Phenibut FAA, Fenibut, Phenybut, Phenigam, Phenigamma, Phenygam, Phenylgam, PhGaba, PGaba, Noofen, Noophen, Anvifen

Motivation

Phenibut is a synthetic relative of the brain’s main calming chemical messenger, built so that it reaches the brain more readily when taken by mouth. It is a prescription medicine in Russia and is sold online in many other countries as a mental-performance product promoted to ease anxiety, improve sleep and sharpen focus. Its appeal to health-minded adults lies in the promise of calm and restful sleep without the familiar sedative prescription drugs.

The compound was developed in the Soviet Union in the 1960s and has been prescribed there for decades for anxiety and poor sleep. Over the past fifteen years it has spread through online stores and self-experimentation communities in Western countries, while poison centers, addiction specialists and the United States food regulator have paid growing attention to it.

This review examines what the human evidence shows about phenibut’s benefits for anxiety, sleep and focus, how strong that evidence is, and what is known about its risks, including tolerance and withdrawal, so that its place in a long-term health and longevity strategy can be weighed.

Benefits - Risks - Protocol - Conclusion

The items below are narrative reviews and primary research giving a high-level overview of the pharmacology, clinical use and risks of phenibut, a GABA (gamma-aminobutyric acid, the brain’s main calming chemical messenger) derivative promoted as a nootropic (cognition enhancer).

No phenibut content was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension or Lifespan.io; none of these platforms has covered phenibut by name.

Grokipedia

  • Phenibut

    A broad encyclopedic entry covering chemistry, receptor pharmacology, Soviet-era history, salt versus free-acid dosage forms, withdrawal, legal status by country and debates on efficacy.

Examine

No Examine article on phenibut exists. Examine does not typically cover prescription medications or substances outside the legal dietary-supplement category; phenibut is prescription-only in Russia (Bonnet 2024) and, according to the US Food and Drug Administration (FDA), does not meet the legal definition of a dietary ingredient in the United States (FDA phenibut page).

ConsumerLab

No ConsumerLab article or product review on phenibut exists, and ConsumerLab has not tested phenibut products. ConsumerLab does not typically cover prescription medications or substances outside the legal dietary-supplement category; phenibut is prescription-only in Russia (Bonnet 2024) and, according to the FDA, not a permitted dietary ingredient in the United States (FDA phenibut page).

Systematic Reviews

The four systematic reviews of phenibut indexed in PubMed all address safety, toxicity and withdrawal; no systematic review or meta-analysis of its claimed benefits exists, so the benefit side of the trade-off is unrepresented.

Mechanism of Action

Phenibut is gamma-aminobutyric acid (GABA, the brain’s main inhibitory chemical messenger) with an added phenyl ring, letting it cross the blood-brain barrier more readily than GABA (Lapin 2001). It is sold as a racemate (a 50:50 mix of two mirror-image forms, R and S).

  • GABA-B receptor activation: R-phenibut activates GABA-B receptors (slow inhibitory receptors that dampen nerve-cell firing), producing calming, sedative and muscle-relaxant effects like its chlorinated analogue baclofen; S-phenibut is inactive there (Dambrova 2008).
  • α2δ calcium-channel binding: Both forms bind the α2δ subunit of voltage-dependent calcium channels (a site that regulates neurotransmitter release), the target of gabapentin and pregabalin. R-phenibut binds it about four times more strongly than GABA-B receptors, so part of its action may be gabapentin-like (Zvejniece 2015, co-authored by employees of manufacturer Olainfarm).
  • Other proposed actions: Russian work describes weak GABA-A activity (fast inhibitory receptors targeted by benzodiazepines), dopamine stimulation and blockade of β-phenethylamine (a natural anxiety-provoking amine) (Lapin 2001).
  • Pharmacokinetics: A toxicology review reports that after a 250 mg oral dose, half-life is about 5.3 hours and 65% is excreted unchanged in urine; only about 0.1% of a dose is expected to reach the brain (Gurley 2024). Russian labeling instead states 80–95% liver metabolism to inactive products (Vidal phenibut label); no cytochrome P450 (liver drug-processing enzyme) pathway has been identified.
  • Selectivity: Affinities at both targets are micromolar (requiring high concentrations), far weaker than baclofen at GABA-B or gabapentin at α2δ, consistent with gram-level doses (Dambrova 2008; Zvejniece 2015).

Historical Context & Evolution

  • Origin: Phenibut was developed in the 1960s, reportedly for the Soviet army (Gurley 2024), and introduced into Russian clinical practice that decade as a tranquilizer with claimed cognition-enhancing effects (Lapin 2001). Swedish clinicians later described it as a former cosmonaut drug (Högberg 2013).
  • Original uses: Russian prescribing covers tension, anxiety and fear, insomnia, pre- and post-operative calming, asthenia (persistent fatigue), post-traumatic stress, stuttering and vestibular (balance-organ) disorders (Lapin 2001), plus alcohol withdrawal and glaucoma as add-on therapy (Vidal phenibut label).
  • Path to self-optimization: In the 2010s, online retailers sold it to Western users, who took it for its anxiety-relieving and euphoric effects; a 2015 snapshot found 48 suppliers selling it cheaply in bulk (Owen 2016).
  • Shift in Western reception: A toxicology review finds English-language literature to consist mostly of case reports of dependence, withdrawal and overdose (Gurley 2024), and United States poison-center calls rose sharply after 2015 (Graves 2020).
  • Competing readings: A Latvian review found trial adverse events rare and case-report doses far above the recommended range, leaving product quality and co-use of other drugs as open questions (Kupats 2020); toxicology reviewers call its effectiveness equivocal and its pharmacology poorly documented (Gurley 2024).

Expected Benefits

Most clinical data come from Russian and Latvian studies without placebo control; one Latvian group’s work includes co-authors employed by Olainfarm (now Olpha), the manufacturer of the phenibut brand Noofen (Vavers 2016; Tērauds 2025).

High 🟩 🟩 🟩

No benefit reaches High: the human trials are open-label comparisons (patients and investigators knew who received the drug) without placebo, only one research group has shown a between-group difference on a validated scale, and the remaining studies are uncontrolled case series.

Medium 🟩 🟩

Reduced Fatigue in Asthenic States

Asthenia (persistent physical and mental fatigue) is a labeled Russian indication (Vidal phenibut label). On the MFI-20 (Multidimensional Fatigue Inventory, a validated fatigue scale), Noofen 500 mg/day reduced fatigue more than betahistine (an anti-vertigo drug) in 58 hypertensive patients (Duma 2016). In 53 randomized patients with cerebrovascular insufficiency (reduced blood flow to the brain), fatigue fell in the Noofen-plus-standard-therapy group, but no comparison with the 20 controls was reported (Vorob’eva 2017). Neither trial used placebo or concealed treatment assignment; healthy adults are untested.

Magnitude: MFI-20 fatigue intensity fell by 30–50% in about three-quarters of Noofen-treated patients; no figure is reported for the control group, not compared between groups (Vorob’eva 2017). Fatigue also fell significantly more with Noofen than with betahistine over 60 days, with no figure reported for the difference (Duma 2016).

Reduced Dizziness

Vestibular dizziness and Ménière’s disease (an inner-ear disorder with vertigo attacks) are labeled indications (Vidal phenibut label). In a controlled trial (Duma, Novosibirsk), 58 hypertensive patients with psychogenic dizziness (dizziness driven by anxiety rather than inner-ear disease) received Noofen 500 mg/day or betahistine (a standard anti-vertigo drug); Noofen reduced dizziness, anxiety, fatigue and headache more than betahistine over 60 days (Duma 2016). The trial had no placebo arm, and healthy adults are untested.

Magnitude: Dizziness severity fell significantly more with Noofen than with betahistine over 60 days; the literature reports no outcome figure for the difference (Duma 2016).

Anxiety Reduction

Anxiety is phenibut’s primary labeled indication, including before procedures (Vidal phenibut label). Noofen 500 mg/day lowered HARS (Hamilton Anxiety Rating Scale, a validated anxiety scale) scores more than betahistine over 60 days (Duma 2016) and matched the anxiolytic (anxiety-reducing) drug adaptol in 62 randomized patients with chronic cerebral ischemia (long-term reduced brain blood flow) (Vorob’eva 2016). Uncontrolled 750–1,500 mg/day courses lowered HADS (Hospital Anxiety and Depression Scale) scores in Kazan cohorts (Esin 2016; Esin 2022) and adjustment-disorder (distress after a life stressor) scores in an Olpha-co-authored Latvian study (Tērauds 2025).

Magnitude: ADNM-20 (adjustment-disorder symptom questionnaire) total score fell 14.8 ± 11.3 points (mean ± standard deviation) after three weeks of 750 mg/day in 90 adults, no control group (Tērauds 2025).

Low 🟩

Improved Sleep Quality ⚠️ Conflicted

Insomnia in older adults is a labeled indication (Vidal phenibut label). A four-week course improved subjective sleep in 67 adults aged 60–70, without an untreated group (Esin 2024). A small controlled study lengthened main sleep stages but not perceived sleep (Danilin 1986). Net: perceived benefit lacks controlled support.

Magnitude: In 12 phenibut-treated versus 10 control patients in early alcohol withdrawal, two major sleep stages lengthened and drowsiness shortened, while sleep onset time and subjective sleep rating did not differ; the literature reports no outcome figure (Danilin 1986).

Cognitive Performance

Phenibut is marketed as a nootropic (cognition enhancer), yet no trial has tested it in healthy adults. In 92 adults with post-COVID-19 cognitive complaints, 1,500 mg/day for 21 days improved cognitive test scores (Esin 2022), but without a control group, so recovery over time cannot be excluded.

Magnitude: MoCA (Montreal Cognitive Assessment, a validated cognitive screening test) median rose from 22 to 25 points and Trail Making Test B (a timed attention and task-switching test) time fell from 281 to 231 seconds, no control group (Esin 2022).

Tension-Type Headache Relief

In 117 adults with tension-type headache, 750 mg/day for three weeks improved sleep and anxiety scores in all patients, and headache burden in episodic but not chronic cases (Esin 2016). The study had no control group.

Magnitude: Headache burden improved in episodic but not chronic tension-type headache; the literature reports no outcome figure (Esin 2016).

Alcohol Withdrawal Support

The Russian label lists phenibut as add-on therapy for alcohol withdrawal and pre-delirium states (early acute confusion) (Vidal phenibut label). The only indexed controlled human study measured sleep architecture (the pattern of sleep stages), not withdrawal severity (Danilin 1986), so the evidence for this outcome is indirect.

Magnitude: Not quantified in available studies. No controlled study has measured withdrawal severity; the only controlled human study measured sleep stages, reported under Improved Sleep Quality (Danilin 1986).

Childhood Tics & Stuttering ⭕️ Not Central to Health & Longevity

Tics, stuttering and enuresis (involuntary urination) in children are labeled indications (Vidal phenibut label). This bears on pediatric neurodevelopment, not adult health or longevity. In 30 children with tics and stuttering, Noofen reduced both (Surushkina 2014), without a control group.

Magnitude: Tics decreased in 80% and stuttering in 66.7% of 30 treated children, no control group (Surushkina 2014).

Speculative 🟨

Neuroprotection After Stroke or Brain Injury

R-phenibut reduced brain damage and improved function in rat stroke and mouse brain-injury models, possibly via calcium-channel and mitochondrial effects (Vavers 2016; Kupats 2020). The basis is animal data only.

Neuropathic Pain Relief

R-phenibut reduced neuropathic (nerve-damage) pain behaviors in rodent nerve-injury models through its gabapentin-like α2δ action (Zvejniece 2015). The basis is mechanistic and animal data only; no human pain trial exists.

Glaucoma Add-On Therapy

The Russian label lists open-angle glaucoma (a chronic eye-pressure optic-nerve disease) as combination therapy, claiming better eye microcirculation (Vidal phenibut label). No human outcome study was found; the basis is the label only.

Motion Sickness Prevention

The Russian label lists prevention of motion sickness (Vidal phenibut label). In rabbits, phenibut before tilting prevented brain vasodilation linked to vestibular stability (Skoromnyi 1991). The basis is label and animal data only.

Obsessive-Compulsive and Personality Disorders

The Russian label lists obsessive-compulsive neurosis (intrusive thoughts and repetitive behaviors) and psychopathy (a personality disorder) among its indications (Vidal phenibut label). No outcome study was found; the basis is the label only.

Neurogenic Urinary Retention ⭕️ Not Central to Health & Longevity

The label lists urinary retention due to myelodysplasia (a congenital spinal-cord malformation) (Vidal phenibut label). This bears on pediatric bladder function, not adult longevity. No outcome study was found; the basis is the label only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant has been linked to phenibut response. Because it is not known to depend on cytochrome P450 enzymes, common drug-metabolism variants are not expected to alter benefit.
  • Baseline biomarkers and symptom levels: No blood biomarker has been linked to response. Trials enrolled symptomatic patients with anxiety, fatigue, dizziness or insomnia; benefits in adults without such symptoms, the usual nootropic user, have not been measured.
  • Sex: No sex-specific efficacy data exist; the adjustment-disorder study was 72% women and showed overall improvement without sex-stratified results (Tērauds 2025).
  • Pre-existing conditions: Headache relief appeared in episodic but not chronic tension-type headache (Esin 2016); benefit with concurrent substance use is unstudied, and 63.2% of published toxicity and withdrawal cases involved it (Weleff 2023).
  • Age: Anxiety scores improved in both 20–40 and 41–70-year subgroups (Esin 2022); older adults with insomnia also reported better sleep (Esin 2024).
  • Course length: Anxiety gains after 21 days faded within a month, whereas 60-day courses kept them for at least a month (Esin 2022).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: trial adverse-event data are pooled without a placebo- or comparison-group rate or named independent groups, and the remaining human evidence is case reports, poison-center series and systematic reviews of case reports.

Medium 🟥 🟥

Daytime Somnolence & Impaired Driving

Somnolence (sleepiness) is the most frequent adverse event at therapeutic doses across 11 clinical trials pooled in a systematic review, and the label advises against driving (Kupats 2020; Vidal phenibut label). A German driving case showed impairment after 1 g with alcohol (Dziadosz 2024). The review gives no comparison-group rate.

Magnitude: Somnolence occurred in 1.89% and any adverse event in 5.66% of 583 trial patients; the review reports no placebo-group rate (Kupats 2020).

Low 🟥

Tolerance, Dependence & Withdrawal Syndrome ⚠️ Conflicted

Daily use produces tolerance: a review of Soviet studies reports 25–33% dose increases after two weeks (Gurley 2024). Abrupt stopping can cause anxiety, insomnia, agitation, psychosis, seizures and neonatal withdrawal (Feldman 2023; Pena 2022). Trial reviews report few labeled-dose adverse events (Kupats 2020). Net: risk concentrates in high-dose daily use.

Magnitude: Among 25 published withdrawal cases (median 10 g/day), 44% needed intensive care, 24% intubation and 8% had seizures; case series, no control group (Feldman 2023).

Central Nervous System Depression, Coma & Death in Overdose ⚠️ Conflicted

Overdose causes sedation, coma and respiratory failure, often with alcohol or benzodiazepines (Weleff 2023); a Minnesota series found 19.6% intubated (McCabe 2019). A death with phenibut as the only drug of misuse is documented (Arndt 2021). German poison-center cases were milder (Bonnet 2024). Net: larger series show severe outcomes.

Magnitude: Of 1,320 US poison-center exposures (2009–2019), 6.2% involved coma, 12.6% major effects and three died; 10.2% had major effects with phenibut alone; no control group (Graves 2020).

Agitation, Anxiety, Psychosis & Delirium

The label lists irritability, agitation and anxiety (Vidal phenibut label); intoxication can cause hallucinations, psychosis and delirium (acute confusion), sometimes requiring sedation and restraint (Li 2017; Martin 2023). Tachycardia (fast heart rate) often accompanies it (Graves 2020).

Magnitude: Agitation occurred in 30.4%, confusion in 21.3% and tachycardia in 21.9% of 1,320 US poison-center exposures; no control group (Graves 2020).

Nausea, Headache, Dizziness & Skin Rash

The label lists nausea with first doses, headache, dizziness and allergic rash or itching as side effects (Vidal phenibut label). Gastrointestinal distress was reported more often with phenibut than with gabapentin or pregabalin in online user reports (Behmer Hansen 2023).

Magnitude: Any adverse event occurred in 5.66% of 583 trial patients, with these effects individually rarer than somnolence; the review reports no placebo-group rate (Kupats 2020).

Liver Effects at High Doses

A toxicology review reports that Russian fact sheets advise liver monitoring with prolonged use and cite fatty liver at ≥7 g/day (Gurley 2024). Microvesicular steatosis (small-droplet liver fat) was found in one fatality (Arndt 2021). The review also notes two overdose case reports without overt liver injury (Gurley 2024).

Magnitude: Not quantified in available studies. Liver evidence is limited to label warnings and single case reports, with no measured incidence.

Speculative 🟨

Falls in Older Adults

Sedation, dizziness and muscle relaxation via GABA-B receptors, as with baclofen, could raise fall risk in older adults (Lapin 2001). The basis is mechanistic only; no fall data exist.

Undisclosed Exposure From Adulterated Products

Cognitive supplements sometimes contain undeclared phenibut alongside other unapproved drugs (Cohen 2021). Health consequences are unmeasured; the basis is product analysis only.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic variant affecting phenibut risk is known; the absence of an identified cytochrome P450 pathway makes common metabolizer variants unlikely modifiers.
  • Baseline kidney and liver function: About 65% of a dose leaves unchanged in urine, per a review (Gurley 2024), so reduced kidney function may raise exposure (inferred); the label advises caution in liver insufficiency and periodic liver and blood-count checks (Vidal phenibut label).
  • Sex: About 80% of published toxicity and withdrawal cases are men, which likely reflects use patterns rather than biology (Weleff 2023); no sex-specific pharmacokinetic data exist.
  • Substance use and psychiatric history: 63.2% of toxicity and withdrawal cases involved other addictive substances, mainly benzodiazepines and alcohol (Weleff 2023); 73% had prior alcohol or drug misuse and 60% anxiety or depression (Stewart 2024).
  • Dose and duration: Withdrawal followed as little as one week of 2–3 g/day (Feldman 2023); case-report doses (0.5–100 g/day) far exceeded the recommended 0.25–2 g/day (Kupats 2020).
  • Age: The label states brain uptake is higher in the young and elderly (Vidal phenibut label); an adolescent case cluster (Isoardi 2020) had severe poisoning at 1.25–1.75 g, per a toxicology review (Gurley 2024); a withdrawal case in a geriatric patient is documented (Wainblat 2023).

Key Interactions & Contraindications

Documented interactions:

  • Hypnotics (sleep-inducing drugs: zolpidem, zopiclone, temazepam): The label states phenibut prolongs and strengthens their effect (Vidal phenibut label); consequence is deeper, longer sedation. Mitigation: no combination, or lowest doses of each and no driving.
  • Opioid analgesics (strong pain-relieving drugs: oxycodone, morphine, tramadol): Avoid. The label states phenibut strengthens opioid effects (Vidal phenibut label); consequence is respiratory depression (dangerously slowed breathing) and coma, a risk highlighted for opiate co-use (Bonnet 2024).
  • Antiepileptics (seizure drugs: gabapentin, pregabalin, carbamazepine, valproate): Label-documented potentiation (Vidal phenibut label); gabapentin and pregabalin also share the α2δ target, adding sedation and dizziness. Mitigation: dose review by the prescriber before any combination.
  • Antipsychotics (drugs for psychosis: quetiapine, olanzapine, haloperidol): The label states phenibut prolongs and strengthens their effect (Vidal phenibut label); consequence is additive sedation. Mitigation: prescriber review and monitoring of alertness.
  • Antiparkinsonian drugs (Parkinson’s disease drugs: levodopa, pramipexole): Label-documented potentiation (Vidal phenibut label); consequence is increased drowsiness and dizziness. Mitigation: prescriber review before combining.
  • Benzodiazepines (alprazolam, clonazepam, diazepam): The label’s hypnotic and antiepileptic classes include them (Vidal phenibut label), and they are among the commonest co-ingestants in severe toxicity (Weleff 2023); consequence is additive sedation, respiratory depression and possible cross-dependence. Mitigation: no concurrent use; any discontinuation under medical supervision.
  • Alcohol: Avoid. The label claims phenibut reduces alcohol’s depressant effect (Vidal phenibut label), yet alcohol is among the most frequent co-ingestants in severe toxicity (Weleff 2023); consequence is unpredictable sedation and impaired driving (Dziadosz 2024).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Baclofen (a muscle relaxant): Same GABA-B receptor target; additive sedation, weakness and confusion. Mitigation: no concurrent self-use; baclofen appears only as a supervised substitute during withdrawal.
  • Over-the-counter sedating antihistamines (allergy and sleep-aid drugs: diphenhydramine, doxylamine): Additive central nervous system depression and next-day impairment. Mitigation: no combination, especially at bedtime with higher phenibut doses.
  • Sedating supplements (kava, valerian, melatonin, ashwagandha, GABA, L-theanine, high-dose magnesium): Additive calming or sedative effects. Mitigation: one agent introduced at a time at low doses, with no driving until the combined effect is known.
  • Kratom and cannabis (THC, tetrahydrocannabinol, the main psychoactive cannabis compound): Additive central nervous system depression and impaired coordination. Mitigation: no combination.
  • Gamma-hydroxybutyrate (GHB) and sodium oxybate (sedatives acting partly at GABA-B receptors): Additive sedation and respiratory depression through the shared receptor. Mitigation: no combination.

Populations who should avoid Phenibut:

  • Pregnancy and breastfeeding: The label advises caution (Vidal phenibut label); neonatal withdrawal requiring treatment followed maternal use throughout pregnancy (Pena 2022).
  • People with current or past substance use disorder: Most dependence and withdrawal cases occur in this group (Stewart 2024).
  • People taking opioids, hypnotics or other central nervous system depressants: Label-documented potentiation (Vidal phenibut label).
  • People with liver insufficiency or erosive or ulcerative gastrointestinal disease: Label cautions (Vidal phenibut label).
  • People with known hypersensitivity to phenibut: The only absolute contraindication on the label (Vidal phenibut label).
  • People with seizure disorders: Inferred from withdrawal seizures in published cases (Feldman 2023); no data on use in epilepsy.
  • People with reduced kidney function: Inferred from largely unchanged kidney excretion in a healthy-volunteer study, per a toxicology review (Gurley 2024); no data in kidney impairment.
  • Drivers and machine operators during use: The label advises avoiding hazardous activities (Vidal phenibut label).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Labeled dose range: The recommended range is 0.25–2 g/day, and reviewed trials reported few adverse events (Kupats 2020); Russian fact sheets, per a review, cap intake at 2.5 g/day (Gurley 2024). This limits overdose, sedation and dependence.
  • Limited daily-use duration: Withdrawal has followed one week of 2–3 g/day (Feldman 2023); restricting continuous courses to three to six weeks, as in Latvian and Russian trials (Tērauds 2025; Esin 2017), reduces tolerance and withdrawal.
  • Dose escalation as a stop signal: Needing more for the same effect signals tolerance (Gurley 2024); stopping or tapering then prevents escalation to the multi-gram doses seen in withdrawal cases.
  • Gradual taper instead of abrupt cessation: After regular daily use, gradual reduction is the approach in published outpatient successes, one over nine weeks from 2.5 g/day (Simon 2026). This prevents rebound anxiety, insomnia and seizures.
  • No combination with alcohol, opioids or benzodiazepines: These are the commonest co-ingestants in severe toxicity (Weleff 2023); avoiding them reduces coma and respiratory-failure risk.
  • No redosing for slow onset: Adolescents (Isoardi 2020) were severely poisoned by repeat doses within three hours, per a toxicology review (Gurley 2024); waiting at least four hours before any additional dose prevents cumulative overdose.
  • Pharmaceutical-grade products: Supplement servings ranged from 21 to 1,164 mg (Cohen 2022); registered medicines reduce accidental overdose from mislabeled content.
  • Liver and blood-count monitoring: The label advises these checks during prolonged use (Vidal phenibut label); baseline and every one to three months during courses detects liver injury early.
  • No driving during use: The label advises abstaining from hazardous activities (Vidal phenibut label); this prevents sedation-related accidents.
  • Early medical care in withdrawal: Symptoms began within hours and worsened over 24 hours in 64% of cases (Feldman 2023); early medical assessment prevents delirium and seizures.

Therapeutic Protocol

Doses are cited; other parameters (timing, course length, titration steps, cycling) reflect common practice unless cited.

  • Labeled single dose: Adults 20–750 mg per dose, with or without food, prescribed by a physician in Russia (Vidal phenibut label).
  • Trial regimens: 250 mg three times daily for three to six weeks (Esin 2016; Tērauds 2025), or 500 mg three times daily for 21–60 days (Esin 2022).
  • Daily ceiling: Russian fact sheets, summarized in a toxicology review, set 2.5 g/day as maximum (Gurley 2024); the Latvian review cites 0.25–2 g/day as the recommended range (Kupats 2020).
  • Competing approaches: Russian practice uses fixed prescribed courses, as reviewed by Lapin of the Bekhterev Psychoneurological Institute (Lapin 2001); Western online users self-dose, averaging 2.4 g (Owen 2016); toxicology reviewers urge cautious restriction of availability (Gurley 2024).
  • Course length: The Kazan group favors at least two months for anxiety (Esin 2022), which conflicts with tolerance seen after two weeks in Soviet studies, per a toxicology review (Gurley 2024).
  • Time of day: For sleep, the elderly-insomnia trial gave 500 mg at 22:00 with smaller morning and afternoon doses (Esin 2024); for daytime anxiety, doses are spread across waking hours.
  • Half-life: About 5.3 hours in a healthy-volunteer study cited by a toxicology review (Gurley 2024); withdrawal symptoms can begin within 3–4 hours of the last dose in dependent users (Samokhvalov 2013).
  • Single versus split dosing: The short half-life explains three-times-daily schedules in trials (Esin 2016); single occasional doses are the common pattern for situational use.
  • Formulation: Powder from opened capsules improved sleep quality and awakening more than intact capsules (Esin 2024), suggesting faster absorption.
  • Genetic polymorphisms: No pharmacogenetic variant is known to require dose adjustment; no cytochrome P450 pathway has been identified.
  • Sex: No sex-based dosing differences are reported; trial cohorts included both sexes without separate dosing (Esin 2024).
  • Age: Older adults aged 60–70 used 1,000–1,250 mg/day in the insomnia trial (Esin 2024); the label notes higher brain uptake in the elderly, favoring lower starting doses.
  • Baseline biomarkers: No biomarker predicts response; baseline liver enzymes, blood count and kidney function identify people needing lower doses or avoidance.
  • Pre-existing conditions: Liver insufficiency and gastrointestinal ulcer disease call for caution (Vidal phenibut label); chronic tension-type headache responded less than episodic (Esin 2016).

Discontinuation & Cycling

  • Short-term, not lifelong: Russian use is course-based, from three weeks to two months (Esin 2022); no data support continuous long-term use.
  • Withdrawal effects: Anxiety, irritability, insomnia, psychosis and seizures can follow abrupt cessation, starting within hours (Feldman 2023).
  • Gradual taper: All published outpatient successes used slow tapers (Feldman 2023); one patient tapered from 2.5 g/day to zero over nine weeks (Simon 2026).
  • Medication-assisted taper: Clinicians have substituted roughly 10 mg baclofen per gram of phenibut, then tapered baclofen (Samokhvalov 2013); baclofen alone failed to prevent a seizure in one case (Patt 2023).
  • Cycling: Tolerance developed within about two weeks in Soviet studies cited by a toxicology review (Gurley 2024); infrequent use, such as no more than once or twice weekly, is the common practice to preserve effect, though untested.
  • Effect after stopping: Anxiety benefit after a 21-day course faded within a month (Esin 2022).

Sourcing and Quality

  • Registered medicines: Pharmaceutical phenibut is sold as Noofen by Olpha in Latvia (Tērauds 2025), as Anvifen in Russia (Esin 2017) and as Fenibut tablets from Russian makers such as Vertex (Vidal phenibut label); they are prescription drugs in Russia (Bonnet 2024).
  • United States legal status of supplements: The FDA states phenibut does not meet the definition of a dietary ingredient, so supplements listing it are misbranded (FDA phenibut page); no lawfully marketed US supplement can list it.
  • Label inaccuracy: Four supplement brands contained 21–1,164 mg per serving, against 250 mg in a typical Russian pharmaceutical tablet (Cohen 2022).
  • Undeclared ingredients: Online phenibut products contained less or more phenibut than declared plus untested additional ingredients (Upmanis 2024); this study’s authors include an Olpha employee.
  • Hidden phenibut: Cognitive-enhancement supplements may contain phenibut without listing it (Cohen 2021).
  • Salt versus free form: Products are sold as phenibut hydrochloride or as the free amino acid; the hydrochloride contains less phenibut per gram, so doses are not interchangeable.
  • Third-party testing: ConsumerLab has not tested phenibut products; an independent certificate of analysis confirming identity and content is the available quality check for non-pharmaceutical products.

Practical Considerations

  • Time to effect: Trials assessed anxiety, fatigue and sleep after three to eight weeks (Tērauds 2025; Duma 2016); acute calming after a single dose is described by users but not measured in trials.
  • Redosing pitfall: Believing an initial dose ineffective and taking more within hours led to severe poisoning in adolescents (Isoardi 2020), as summarized in a toxicology review (Gurley 2024).
  • Escalation pitfall: Most published withdrawal cases describe raising initial doses that had become ineffective, ending at many grams daily, per a toxicology review (Gurley 2024).
  • Drug-screen pitfall: Urine or blood screening for phenibut is not widely available, so intoxication or withdrawal may be missed in emergencies (Penzak 2024).
  • Regulatory status: Prescription-only in Russia (Bonnet 2024); in the United States, not a lawful dietary ingredient, and in 2023 a court enjoined a seller whose phenibut beverage the FDA called an unsafe food additive (FDA phenibut page).
  • FDA action and market response: After the 2019 FDA warning letters (FDA constituent update), phenibut content rose in three of four tracked brands (Cohen 2022).
  • Cost and payers: Phenibut is inexpensive online (Owen 2016), and the competing anxiety and sleep drugs are cheap generics, so no systematic payer incentive favoring one over the other is evident.

Interaction with Foundational Habits

  • Sleep: Direct, potentiating at bedtime: in alcohol-withdrawal patients, phenibut shortened drowsiness stages and lengthened main sleep stages without changing sleep onset (Danilin 1986). Blunting on cessation: rebound insomnia is among the most common withdrawal symptoms (Weleff 2023). Sleep hygiene and cognitive behavioral therapy for insomnia remain the base.
  • Nutrition: No direct interaction: the label allows dosing with or without food (Vidal phenibut label), and no nutrient depletion is known. Alcohol is the key dietary exposure to avoid because of combined sedation in toxicity cases (Weleff 2023).
  • Exercise: Indirect, potentially blunting: sedation, dizziness and muscle relaxation may impair coordination and training quality (inferred from GABA-B pharmacology shared with baclofen). Conversely, a single 250 mg dose preserved working capacity during heavy exertion in protective gear (Makarov 1997). Taking it after demanding or skill-based sessions avoids performance and injury effects.
  • Stress management: Direct, potentiating short term: anxiolytic effects lower perceived stress in symptomatic patients (Tērauds 2025). Long-term blunting risk: a professional using it for years against work stress developed tolerance and repeated hospitalizations (Martin 2023; summarized in a toxicology review, Gurley 2024); meditation, breathing work or therapy remain the base.

Monitoring Protocol & Defining Success

Before a course, baseline testing establishes liver function, blood counts and kidney function, because the Russian label advises liver and blood-count checks during prolonged use and phenibut is largely cleared by the kidneys. Baseline ratings of anxiety, sleep and daytime alertness give a personal reference point, since no biomarker tracks benefit.

Ongoing monitoring follows a simple cadence: repeat liver enzymes and blood count at 4 weeks, then every 1–3 months while use continues, and repeat kidney function every 3–6 months. Symptom ratings are repeated weekly during the first month and then monthly. Any need to raise the dose for the same effect, rebound anxiety between doses or withdrawal-like symptoms after a missed dose marks tolerance and is the clearest signal that the risk side is growing. Success means fewer symptoms at a stable or falling dose.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 7–56 U/L (standard reference range) Safety check: rising values stop use ALT (alanine aminotransferase, a liver enzyme); label advises liver monitoring with prolonged use (Vidal phenibut label); ranges vary by laboratory; no fasting required
AST 10–40 U/L (standard reference range) Safety check: rising values stop use AST (aspartate aminotransferase, a liver and muscle enzyme); pair with ALT; recent hard exercise can raise AST
Complete blood count with differential Hemoglobin 13.5–17.5 g/dL men, 12.0–15.5 g/dL women; white cells 4.5–11.0 × 10⁹/L (standard reference range) Safety check: abnormal counts stop use Label advises peripheral blood monitoring with prolonged use (Vidal phenibut label)
Serum creatinine 0.7–1.3 mg/dL men, 0.6–1.1 mg/dL women (standard reference range) Safety check: impaired clearance changes dose Phenibut is largely excreted unchanged in urine, per a toxicology review (Gurley 2024); report with eGFR (estimated glomerular filtration rate, a kidney-function estimate)

Qualitative markers:

  • Anxiety level: Self-rated daily tension and worry, compared with baseline.
  • Sleep quality: Time to fall asleep, night awakenings and morning refreshment.
  • Daytime alertness: Drowsiness, reaction time and fitness to drive the morning after evening doses.
  • Fatigue: Physical and mental energy across the day.
  • Tolerance signals: Gradual dose escalation, shorter duration of effect, or craving.
  • Withdrawal signals: Irritability, insomnia or tremor after a delayed or missed dose.

Emerging Research

  • Registered trials: A November 2026 ClinicalTrials.gov search found no phenibut, Noofen or Anvifen trials (no NCT ID, the registry’s trial identifier, exists), so no ongoing trial is expected to change the current picture soon.
  • Placebo-controlled efficacy: Supportive Russian and Latvian studies, including manufacturer co-authored work (Tērauds 2025), lack placebo arms; a blinded trial in anxiety or insomnia would strengthen or weaken the benefit case decisively.
  • R-phenibut as a neuroprotectant: The single active mirror-image form protected brain tissue in stroke and injury models (Vavers 2016; Kupats 2020); this manufacturer-linked line could open a narrower medical use but has no human data.
  • Withdrawal treatment: Debate over baclofen versus benzodiazepines and phenobarbital continues (Feldman 2024; Penzak 2024); standardized protocols would clarify how safely dependence can be reversed.
  • Exposure surveillance: New hair-testing (Racines 2026) and wastewater methods (Gomes 2026) could reveal how common harmful use is relative to uneventful use, refining risk estimates in either direction.
  • Healthy-adult and longevity data: Healthy-adult studies are few: a pharmacokinetic study (Zhezlova 2011), a 1990s Russian heat-tolerance study under heavy exertion (Makarov 1997) and an archival analysis of situational anxiety during stressful work (Ivanov 2015); none examined long-term or aging outcomes, so such data would be the first direct evidence for this audience.

Conclusion

Phenibut is a calming drug from the Soviet era that acts on the same brain systems as some prescription muscle relaxants and nerve-pain drugs. In Russia it is a prescription medicine for anxiety, poor sleep, fatigue and dizziness; elsewhere it circulates mainly as an online product promoted for calm and focus.

The case for benefit rests on modest ground. One small controlled study found less fatigue, dizziness and anxiety than with a comparison drug, while several uncontrolled studies describe less anxiety, better sleep and clearer thinking. None used a dummy treatment, none involved healthy adults, and part of the supportive work comes from researchers working with the drug’s Latvian manufacturer. Nothing is known about effects on aging or lifespan.

The risk side is documented more often, though mostly through individual case reports and poison-center records. Tolerance can develop within weeks, and stopping after heavy daily use can bring a severe withdrawal that sometimes needs hospital care. Overdoses, especially with alcohol or other sedatives, can lead to deep sedation, coma and, rarely, death. Products bought online often contain more or less of the drug than their labels state.

For a health-focused adult, the picture is a drug with uncertain, mostly short-term benefits for specific symptoms, a clear potential for dependence, and a poor fit with long-term daily use. Brief, low-dose, infrequent use of a pharmaceutical product sits at the lower end of the documented risk, while frequent high-dose use carries most of the reported harm.

Top - Benefits - Risks - Protocol